Abbott Laboratories logo

Abbott Laboratories (ABT)

Market Closed
5 Dec, 20:00
NYSE NYSE
$
125. 08
-0.32
-0.26%
$
223.73B Market Cap
36.49 P/E Ratio
2.2% Div Yield
3,295,006 Volume
4.44 Eps
$ 125.4
Previous Close
Day Range
124.64 126.05
Year Range
110.86 141.23
Want to track ABT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 45 days
Abbott (ABT) Gets FDA Nod for Two Glucose Monitoring Systems

Abbott (ABT) Gets FDA Nod for Two Glucose Monitoring Systems

Abbott's (ABT) glucose monitoring systems - Lingo and Libre Rio - based on Freestyle Libre technology, receive FDA clearance.

Zacks | 1 year ago
2 Healthcare Stocks to Buy Hand Over Fist in June

2 Healthcare Stocks to Buy Hand Over Fist in June

Vertex Pharmaceuticals and Abbott Laboratories are innovative healthcare leaders. Both companies have robust businesses and excellent potential opportunities.

Fool | 1 year ago
Abbott (ABT) Stock Sinks As Market Gains: Here's Why

Abbott (ABT) Stock Sinks As Market Gains: Here's Why

Abbott (ABT) closed the most recent trading day at $105.81, moving -1.56% from the previous trading session.

Zacks | 1 year ago
2 Magnificent Dividend Growth Stocks to Buy Now

2 Magnificent Dividend Growth Stocks to Buy Now

Dividend growth stocks are superb wealth-creation vehicles. These two blue chips are among the best in the category.

Fool | 1 year ago
FDA approves two new Abbott over-the-counter continuous glucose monitors

FDA approves two new Abbott over-the-counter continuous glucose monitors

Abbott on Monday announced it has received FDA clearance for two new CGMs that will be available without a prescription. A CGM is a small sensor that pokes through the skin and tracks a person's glucose levels in real-time.

Cnbc | 1 year ago
US FDA clears Abbott's continuous glucose monitors for over-the-counter use

US FDA clears Abbott's continuous glucose monitors for over-the-counter use

Abbott said on Monday that the U.S. Food and Drug Administration has cleared its two continuous glucose monitoring systems for over-the-counter use.

Reuters | 1 year ago
The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash

The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash

From 1930 to 2023, 70% of dividend stocks in the top two quintiles outperformed the S&P 500 during recessions. Dividends have contributed 40% of the stock market gain since 1930, increasing with rising inflation.

Investorplace | 1 year ago
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?

Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Zacks | 1 year ago
Abbott (ABT) Stock Dips While Market Gains: Key Facts

Abbott (ABT) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Abbott (ABT) stood at $103.23, denoting a -0.19% change from the preceding trading day.

Zacks | 1 year ago
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 year ago
The 2 Most Important Charts I Want (Dividend) Investors To See

The 2 Most Important Charts I Want (Dividend) Investors To See

Recent data indicates a heightened risk of stagflation, with slowing economic growth and persistent inflation. This poses challenges for the economy and portfolios, but also presents opportunities to buy beaten-down stocks with strong pricing power and growth potential. My focus remains on resilient dividend growth stocks and sectors like energy and healthcare, which are well-positioned for these conditions.

Seekingalpha | 1 year ago
Abbott Laboratories: Why I Agree With Wall Street On This One

Abbott Laboratories: Why I Agree With Wall Street On This One

Wall Street analysts have a 'strong buy' rating on ABT stock, with 12 out of 24 analysts giving it this rating in the last 90 days. We agree with such bullish sentiment. Despite some risks, ABT stock has the potential to outperform the overall market by a large margin.

Seekingalpha | 1 year ago
Loading...
Load More